electroCore Announces Issuance of New Patent for Migraine Treatment using Smartphones
27 Julho 2021 - 9:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage
bioelectronic medicine company, today announced that the United
States Patent and Trademark Office (USPTO) has issued U.S. Patent
No. 11,065,444 to electroCore, relating to the use of a mobile
phone for stimulating the trigeminal nerve to treat disorders.
The newly issued patent includes descriptions of devices and
methods that allow a patient to self-treat a medical condition,
such as migraine headache, by non-invasive electrical stimulation
of nerves of the head, particularly supraorbital, supratrochlear,
infraorbital, and mental nerves in the vicinity of their foramen or
notch. The system comprises a handheld mobile device, such as a
smartphone, that is applied to the surface of the patient's head.
One or more electrodes apply electrical impulses through the
patient's skin modulating a targeted nerve to treat the medical
condition. The system is designed to address problems that arise
particularly during self-treatment, when a medical professional is
not present.
This newly allowed patent is owned by electroCore and is the
latest U.S. patent to issue in connection with the company’s
non-invasive development program for pain.
“We are pleased with the continued advancement of electroCore’s
non-invasive approaches to treating patients,” commented JP
Errico, a founder, board member and investor of electroCore, who
was also an inventor of the new patent. “These new developments
expand the breadth and ease of use by which electroCore’s therapy
may be deployed, enabling even more patients worldwide to receive
much needed relief at home.”About electroCore,
Inc.electroCore, Inc. is a commercial stage
bioelectronic medicine company dedicated to improving patient
outcomes through its non-invasive vagus nerve stimulation therapy
platform, initially focused on the treatment of multiple conditions
in neurology. The company's current indications are the preventive
treatment of cluster headache and migraine and the acute treatment
of migraine and episodic cluster headache.
For more information, visit www.electrocore.com.
About gammaCoreTMgammaCoreTM
(nVNS) is the first non-invasive, hand-held medical therapy applied
at the neck as an adjunctive therapy to treat migraine and cluster
headache through the utilization of a mild electrical stimulation
to the vagus nerve that passes through the skin. Designed as a
portable, easy-to-use technology, gammaCore can be
self-administered by patients, as needed, without the potential
side effects associated with commonly prescribed drugs. When placed
on a patient’s neck over the vagus nerve, gammaCore stimulates the
nerve’s afferent fibers, which may lead to a reduction of pain in
patients.
gammaCore (nVNS) is FDA cleared in the United States for
adjunctive use for the preventive treatment of cluster headache in
adult patients, the acute treatment of pain associated with
episodic cluster headache in adult patients, and the acute and
preventive treatment of migraine in adolescent (ages 12 and older)
and adult patients. gammaCore is CE-marked in the European Union
for the acute and/or prophylactic treatment of primary headache
(Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and
Hemicrania Continua) and Medication Overuse Headache in adults.
gammaCore is contraindicated for patients if they:
- Have an active implantable medical device, such as a pacemaker,
hearing aid implant, or any implanted electronic device
- Have a metallic device, such as a stent, bone plate, or bone
screw, implanted at or near the neck
- Are using another device at the same time (e.g., TENS Unit,
muscle stimulator) or any portable electronic device (e.g., mobile
phone)
Safety and efficacy of gammaCore have not been evaluated in the
following patients:
- Patients diagnosed with narrowing of the arteries (carotid
atherosclerosis)
- Patients who have had surgery to cut the vagus nerve in the
neck (cervical vagotomy)
- Pediatric patients (less than 12 years)
- Pregnant women
- Patients with clinically significant hypertension, hypotension,
bradycardia, or tachycardia
Please refer to the gammaCore Instructions for Use for all of
the important warnings and precautions before using or prescribing
this product.
Forward-Looking StatementsThis press release
and other written and oral statements made by representatives of
electroCore may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements about electroCore's business prospects and clinical and
product development plans; its pipeline or potential markets for
its technologies; the timing, outcome and impact of regulatory,
clinical and commercial developments; the availability and impact
of payer coverage, the potential of nVNS generally and gammaCore in
particular and other statements that are not historical in nature,
particularly those that utilize terminology such as "anticipates,"
"will," "expects," "believes," "intends," other words of similar
meaning, derivations of such words and the use of future dates.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the ability to raise the additional funding
needed to continue to pursue electroCore’s business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, the ability to
commercialize gammaCore™, the potential impact and effects of
COVID-19 on the business of electroCore, electroCore’s results of
operations and financial performance, and any measures electroCore
has and may take in response to COVID-19 and any expectations
electroCore may have with respect thereto, competition in the
industry in which electroCore operates and overall market
conditions. Any forward-looking statements are made as of the date
of this press release, and electroCore assumes no obligation to
update the forward-looking statements or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents electroCore files with the SEC available at
www.sec.gov.
Investors:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital
or
Media Contact:
Jackie Dorsky
electroCore
908-313-6331
Jackie.dorsky@electrocore.com
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024